Breast Implant Settlement Calculator 2026: What the BIA-ALCL Record Shows
Use the Breast Implant Settlement Calculator to organize potential claim factors involving a confirmed BIA-ALCL diagnosis, textured implant exposure, serious implant complications, explant surgery, reconstruction revision, FDA-described systemic symptoms, medical expenses, lost income and other documented damages.
- Separates confirmed BIA-ALCL from systemic-symptom and other complication pathways.
- Captures implant manufacturer, model, texture, serial/lot information and recall history.
- Organizes pathology, explant, oncology, reconstruction and damages records.
- Uses FDA and federal-court sources without treating allegations as proven causation.
Get Your Breast Implant Claim Estimate
Answer the guided questions using your diagnosis, implant history, pathology, treatment, explant/revision records and documented losses.
Who May Need a Breast Implant Claim Review?
Potential claims are highly fact-specific and can depend on diagnosis, implant texture and model, manufacturer, pathology, surgery history, recall information, treatment, damages, causation evidence, state law and filing deadlines.
Facts That May Support Closer Review
- Confirmed BIA-ALCL supported by pathology or cytology
- History of textured breast implants or tissue expanders
- Known manufacturer, model, serial number or patient device card
- Explant surgery, capsulectomy, oncology treatment or reconstruction revision
- Documented medical expenses, wage loss or long-term monitoring
Claims Requiring More Review
- Systemic symptoms without a formal BIA-ALCL diagnosis
- Unknown implant manufacturer, model or surface texture
- Implants removed years ago with incomplete records
- Symptoms with multiple potential medical explanations
- Unclear diagnosis, discovery date or filing deadline
Breast Implant Compensation: What the Record Actually Shows
No public source states what a BIA-ALCL claim is worth. AbbVie settled substantially all United States ALCL lawsuits in June 2026 and disclosed no amount; no court order, wire report or regulatory filing contains one. What follows is what is actually on the record — the settlement’s existence, the cases it left behind, and the FDA’s own count of the harm.
A settlement exists. The amount does not.
Not disclosedAbbVie states that in June 2026 it reached an agreement to resolve substantially all United States BIA-ALCL lawsuits, to be dismissed with prejudice. No amount, no fund size and no per-claimant allocation appears in that filing, in any press release, or in any court order.
AbbVie’s Form 10-Q filed 3 August 2026.What the settlement left behind
1,370 federal casesThe JPML report of 1 September 2026 counts 1,370 actions before Judge Brian R. Martinotti in New Jersey. AbbVie separately reports roughly 475 lawsuits in U.S. state courts and 1,080 abroad. Rupture and breast implant illness claims are not consolidated at all.
JPML pending-MDL report; AbbVie Form 10-Q.What the recall actually documented
1,380 reports, 64 deathsThe FDA requested Allergan’s worldwide BIOCELL recall on 24 July 2019, covering 246,831 implants, after identifying 573 BIA-ALCL cases and 33 deaths. Cumulative reporting through 30 June 2024 records 1,380 device reports and 64 deaths, 1,182 of them (86%) attributed to Allergan.
FDA’s recall announcement; FDA’s cumulative reporting.The only published per-claimant figures
Dow Corning, 1990sNo breast implant programme since Dow Corning has published what individual claimants receive. That settlement facility paid disease amounts from $12,000 to $300,000 in its highest class, with expedited release payments of $2,000, $1,200 or $600. Its rupture deadline expired in 2006, so it is a reference point, not a route.
Court-appointed Claimants’ Advisory Committee notice, 2018.What Is Known About Breast Implant Compensation, and What Is Not
In June 2026 AbbVie, which acquired Allergan in 2020, reached an agreement to resolve substantially all United States BIA-ALCL lawsuits. The company disclosed the agreement in its Form 10-Q filed 3 August 2026 and said the cases will be dismissed with prejudice. It disclosed nothing else — no total, no fund, no allocation method, no per-claimant range. That silence is ordinary in mass-tort settlements, and it is also the most important fact for anyone trying to value a claim today: there is no benchmark, because none has been made public.
One number from that same filing is widely misused. AbbVie reports a litigation accrual of approximately $1.7 billion as of 30 June 2026. That is the company’s total reserve across every legal proceeding it faces — not a BIOCELL figure — and the filing states plainly that AbbVie is unable to estimate possible loss beyond the amounts accrued. It appears on several websites as though it were the implant settlement. It is not, and a claimant who plans around it is planning around a number that does not describe this litigation.
The settlement also did not end the litigation. The JPML’s 1 September 2026 report still counts 1,370 actions in MDL 2921 before Judge Brian R. Martinotti, and AbbVie separately reports roughly 475 lawsuits in U.S. state courts and about 1,080 in other countries including Australia, Brazil, Canada and South Korea. Claims that are not BIA-ALCL — rupture, and what is commonly called breast implant illness — sit outside the consolidated proceeding entirely, with no settlement and no published figures of any kind.
The regulatory record is the part that is fully public. The FDA requested Allergan’s worldwide recall of BIOCELL textured implants and tissue expanders on 24 July 2019, a Class I recall covering 246,831 implants, after identifying 573 BIA-ALCL cases and 33 deaths worldwide. Its cumulative reporting through 30 June 2024 records 1,380 medical device reports and 64 deaths, with 1,182 of those reports — 86% — attributed to Allergan products. The agency has consistently said it does not recommend removal of textured implants in people without symptoms, which matters for anyone weighing explant surgery on the strength of the recall alone.
What a claim can actually allege was narrowed in March 2021, when the MDL court ruled on motions to dismiss. Label-based failure-to-warn claims were dismissed as preempted by federal device law. What survived was report-based failure to warn, manufacturing defect, negligence per se, implied warranty, consumer fraud, and — significantly — medical monitoring, with the court holding that a plaintiff does not need a current BIA-ALCL diagnosis to pursue it. The first surgical explant bellwether trial is set for 19 October 2026. Readers comparing device litigation may find the hernia mesh claim guide useful, since it turns on the same preemption framework.
BIA-ALCL: Diagnosis, Implant Texture & FDA Reporting
BIA-ALCL is a T-cell lymphoma that can develop in the capsule or fluid around a breast implant. FDA states that risk is higher with textured-surface implants than smooth-surface implants.
FDA’s currently published MDR review reports 1,380 BIA-ALCL cases through June 30, 2024. FDA’s prior death table reported 63 deaths through June 30, 2023. FDA cautions that MDR data cannot by themselves calculate true incidence or prove individual causation.
Common Presentation
FDA advises patients to discuss persistent swelling, a mass, pain or other changes around an implant with a clinician.
Texture Matters
FDA says BIA-ALCL risk is higher for textured implants than smooth implants.
Diagnosis Evidence
Pathology, cytology, CD30 testing, imaging and oncology records can be critical.
Breast Implant Illness Symptoms: What FDA Says
FDA lists reported systemic symptoms such as fatigue, memory or concentration problems, joint and muscle pain, hair loss, weight changes, anxiety and depression.
FDA’s review identified 10,318 MDRs meeting systemic-symptom search criteria from January 1, 2008 through June 30, 2024 after duplicates were removed. FDA states that the cause of these symptoms and the degree to which they may be related to implants remain unclear. BII is not currently recognized as a formal medical diagnosis and there are no specific accepted diagnostic criteria.
Evidence That Can Strengthen a Breast Implant Claim Review
- Patient device card with manufacturer, model, serial or lot number
- Implantation operative report
- Surface texture and manufacturer information
- Explant, capsulectomy and reconstruction records
- Pathology, cytology and CD30/ALK testing where applicable
- Oncology, hematology and imaging records
- Systemic-symptom and specialist records
- Photos and symptom timeline
- Medical bills and out-of-pocket costs
- Lost wages and reduced-earning documentation
- Therapy, counseling or caregiving expenses
- Scarring, pain and quality-of-life documentation
Allergan BIOCELL Textured Breast Implant MDL 2921
The U.S. District Court for the District of New Jersey continues to maintain Master Docket 2:19-md-2921. The court identifies Judge Brian R. Martinotti and Magistrate Judge Leda Dunn Wettre and directs users to PACER for the latest filings.
MDL 2921 does not establish liability or compensation for every claimant. Product identity, BIOCELL exposure, diagnosis, causation, law and damages remain case-specific.
Why the 2019 Allergan BIOCELL Recall Still Matters
FDA requested recall of specified Allergan BIOCELL textured breast implants and tissue expanders because of BIA-ALCL risk. At the time, FDA reported that its analysis showed the BIA-ALCL risk with Allergan BIOCELL textured implants was approximately six times the risk with textured implants from other manufacturers marketing in the United States.
FDA did not recommend routine removal of textured implants in patients without symptoms solely because of the recall due to surgical risks.
What Can Affect Breast Implant Settlement Value?
Diagnosis Strength
Confirmed BIA-ALCL with pathology and oncology records is materially different from a symptom-only claim.
Implant Identification
Manufacturer, model, texture, serial/lot number and recall status can determine which product allegations matter.
Treatment Burden
Explant surgery, capsulectomy, reconstruction revision, chemotherapy, radiation and monitoring can increase documented losses.
Economic Damages
Medical expenses, lost wages, reduced earning capacity, travel and future care may affect value.
Personal Impact
Scarring, pain, emotional distress and long-term limitations may be relevant where recoverable.
Causation & Legal Risk
Alternative explanations, experts, state law, deadlines and defendant-specific defenses can materially affect value.
Breast Implant Lawsuit Filing Deadlines
There is no single national statute of limitations for every breast implant claim. Deadlines can depend on state law, diagnosis, discovery of a potential connection, explant date, recall information and other facts.
Related TortAdvisor Resources
Breast Implant Settlement Calculator FAQ
What does the calculator estimate?
It organizes diagnosis, implant type, product identification, pathology, treatment, explant history, medical expenses, lost income and other damages into an educational range.
Is BIA-ALCL breast cancer?
No. FDA describes BIA-ALCL as a T-cell lymphoma, not cancer of breast tissue.
Are textured implants associated with higher risk?
Yes. FDA states BIA-ALCL risk is higher with textured-surface implants than smooth-surface implants.
Is breast implant illness a formal diagnosis?
FDA says BII is not currently recognized as a formal medical diagnosis and causation remains unclear.
Does an Allergan recall automatically create a lawsuit?
No. Recall status can matter, but a claim still depends on product identity, injury, causation, law, deadlines and damages.
Does using the calculator create an attorney-client relationship?
No. Representation requires acceptance by a licensed attorney and an engagement agreement.
Request a Free Breast Implant Case Review
If you were diagnosed with BIA-ALCL or experienced serious complications after breast implants, use the calculator to organize your records or request a confidential screening.
Where These Figures Come From
Every figure on this page comes from a primary record: AbbVie’s filings with the Securities and Exchange Commission, the FDA’s recall announcement and its cumulative device-report data, orders of the MDL 2921 court, and the Judicial Panel on Multidistrict Litigation’s pending-case report dated 1 September 2026.
We publish no estimated, averaged or projected settlement value for BIA-ALCL or any other breast implant claim, because no public source supports one. Where a figure circulates widely but cannot be traced to a primary record — including per-claimant ranges of “$50,000 to $300,000” that appear on law firm sites, and AbbVie’s company-wide $1.7 billion litigation accrual presented as though it were the implant settlement — we say so rather than repeat it. Where a number genuinely does not exist, this page says that plainly instead of offering one.
FDA & Federal Court Breast Implant Sources
FDA — BIA-ALCL Medical Device Reports
FDA’s published MDR review, including 1,380 reported BIA-ALCL cases through June 30, 2024 and reporting limitations.
Open FDA MDR review →FDA — BIA-ALCL Questions & Answers
FDA guidance on implant texture, symptoms, risk and device identification.
Open FDA Q&A →FDA — Systemic Symptoms / BII MDR Review
FDA’s review of systemic-symptom reports and current statement that BII is not a formal diagnosis.
Open FDA systemic-symptom review →FDA — Allergan BIOCELL Recall
FDA’s 2019 action requesting recall of specified Allergan BIOCELL textured implants and tissue expanders.
Open FDA recall announcement →FDA — Breast Implant Safety Requirements
FDA information on boxed warnings, patient decision checklists and patient device cards.
Open FDA safety page →District of New Jersey — MDL 2921
Official court page for Allergan BIOCELL Textured Breast Implant Products Liability Litigation.
Open MDL 2921 page →
